Abstracts tagged "adult-onset Still’s disease and familial Mediterranean fever"

Abstract Number: 264 • 2015 ACR/ARHP Annual Meeting
Clinical Phenotype and Response to Treatment in Adult-Onset Still’s Disease with MEFV Variants
Fumiaki Nonaka¹, Toshimasa Shimizu², Katsumi Eguchi³, Masataka Umeda⁴, Yukitaka Ueki⁵, Keita Fujikawa⁶, Akinari Mizokami⁷, Munetoshi Nakashima⁸, Michio Yasunami⁹, Naoki Iwamoto⁴, Atsushi Kawakami², Yuka Jiuchi¹⁰ and Kiyoshi Migita¹⁰, ¹Department of Rheumatology and Metabloism, Sasebo City General Hospital, Sasebo, Japan, ²Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Department of Rheumatology, Sasebo Chuo Hospital, Sasebo, Japan, ⁴Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, ⁵Kyushu multicenter rheumatoid arthritis ultrasound prospective observational cohort study group, Nagasaki, Japan, ⁶Arthritis and Connective Tissue Disease, Isahaya Health Insurance General Hospital, Isahaya, Japan, ⁷Department of Rheumatology, Isahaya Health Insurance General Hospital, Isahaya, Japan, ⁸Department of Rheumatology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, ⁹Nagasaki University Institute of Tropical Medicine (NEKKEN), Nagasaki, Japan, ¹⁰Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Japan
Background/Purpose: Adult-onset Still’s disease (AOSD) is a rare inflammatory disorder that has been recently classified as a polygenic autoinflammatory disorder. Patients with Familial Mediterranean Fever…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].